Pharmacology, Toxicology and Pharmaceutical Science
Afatinib
32%
Albumin
32%
Alprenolol
8%
Atezolizumab
32%
Bone Marrow Suppression
7%
Carboplatin
6%
Diarrhea
6%
Docetaxel
64%
Drug-Drug Interaction
32%
Epidermal Growth Factor Receptor
40%
Erlotinib
32%
Etoposide
18%
Febrile Neutropenia
8%
Glycogen Synthase Kinase
12%
Lung Adenocarcinoma
32%
Metastatic Breast Cancer
72%
Monotherapy
15%
Mortality Rate
8%
Neoplasm
68%
Neutropenia
15%
Non Small Cell Lung Cancer
36%
Overall Survival
43%
Pembrolizumab
96%
Pemetrexed
6%
Pertuzumab
64%
Pharmacokinetic Parameter
8%
Pharmacokinetics
32%
Phase II Trials
32%
Phase IV
32%
Placebo
85%
Programmed Cell Death
5%
Programmed Death 1 Ligand 1
32%
Progression Free Survival
41%
Randomized Clinical Trial
32%
Serum Albumin
8%
Small Cell Lung Cancer
64%
Survival Rate
6%
Trastuzumab
96%
Trilaciclib
64%
Vinorelbine
32%
Zeneca
8%
Medicine and Dentistry
Albumin
32%
Alprenolol
8%
Atezolizumab
32%
Bone Marrow Suppression
7%
Cancer of Unknown Primary Origin
32%
Carboplatin
6%
Cumulative Incidence
8%
Docetaxel
32%
Doctor of Philosophy
8%
Drug Dose Reduction
8%
Epidermal Growth Factor Receptor
44%
Erythrocyte Transfusion
8%
Etoposide
18%
Hazard Ratio
7%
Hematopoietic Cell
15%
Intention-to-Treat Analysis
11%
Lung Adenocarcinoma
32%
Metastatic Breast Cancer
32%
Monotherapy
17%
Mortality Rate
8%
Neoplasm
100%
Neutropenia
13%
Non Small Cell Lung Cancer
68%
Overall Survival
38%
Pembrolizumab
96%
Pemetrexed
6%
Pertuzumab
32%
Phase II Trials
32%
Placebo
84%
Pooled Analysis
8%
Positron Emission Tomography
32%
Programmed Death 1 Ligand 1
64%
Progression Free Survival
30%
Prospective Study
8%
Serum Albumin
8%
Small Cell Lung Cancer
64%
Survival Rate
6%
Trastuzumab
32%
Trilaciclib
64%
